DATE: May 30, 2002 SHEET _1_ of _1_

Form PTO - 1449 (Modified)

FORM PTO-1449 (Modified) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 6791.US.02	SERIAL NO. 10/081,207
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	APPLICANT(S) M. Cowart *et al.*	
(Use several sheets if necessary)	FILING DATE Febuary 25, 2002	GROUP ART NO. 1642
(37 CFR 1.98 (b))		

U.S.PATENT DOCUMENTS

EXAMINER INITIAL		PATENT NUMBER	ISSUE DATE	INVENTOR	CLASS	SUB CLASS	FILING DATE
VB	A1	US 4,297,369	10/27/1981	Takizawa *et al.*	424	285	07/28/1980
VB	A2	US 4,447,620	05/08/1984	Sih *et al.*	548	336	10/12/1982
VB	A3	US 4,452,986	06/05/1984	Johnson *et al.*	548	336	09/30/1982
VB	A4	US 5,648,372	07/15/1997	Naito *et al.*	514	383	02/01/1995
~~VB~~							
~~VB~~							

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION

		DOCUMENT NUMBER	PUBLIC-ATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUB CLASS	TRANS-LATION YES	TRANS-LATION NO
VB	B1	0 169 012 A1	22.01.1986	EP				
VB	B2	94/26738	24.11.1994	WO				
VB	B3	0 978 512 A1	09.02.2000	EP				
VB	B4	00/06254	10.02.2000	WO				

OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)

VB	C1	LEURS, R., *et al.* "Therapeutic potential of histamine H_3 receptor agonists and antagonists", Trends in Pharmacological Sciences 1998, Vol. 19 (5), pp. 177-183 (May 1998)
VB	C2	HAAS, H., *et al.* "Subcortical modulation of synaptic plasticity in the hippocampus", Behavioural Brain Research, Germany, Vol. 66, pp. 41-44 (Jan. 1995)
VB	C3	SCHWARTZ, J., *et al.* "Histaminergic transmission in the mammalian brain", Physiological Reviews, France, Vol. 71, No. 1, pp. 1-51 (Jan. 1991)

EXAMINER V. Balasubramaniam DATE CONSIDERED 6/24/04

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

(Form PTO 1449)

#5

DATE rch 19, 2003 SHEET _1_ of _1_

Form PTO - 1449 (Modified)

FORM PTO-1449 (Modified) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 6791.US.02	SERIAL NO. 10/081,207
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	APPLICANT(S) Cowart, et al.	
	FILING DATE February 22, 2002	GROUP 1624

OIPE JC58 MAR 24 2003 PATENT & TRADEMARK OFFICE

RECEIVED MAR 26 2003 TECH CENTER 1600/2900

(37 CFR 1.98 (b))

U.S.PATENT DOCUMENTS

EXAMINER INITIAL		PATENT NUMBER	ISSUE DATE	INVENTOR	CLASS	SUB CLASS	FILING DATE
VB	A1	3,903,092	09/02/1975	Chapman et al.	260	293	10/24/1972
VB	A2	3,910,955	10/07/1975	Chapman et al.	260	330	06/18/1973
VB	A3	4,237,144	12/02/1980	Cragoe et al.	424	270	06/21/1979
VB	A4	4,495,357	01/22/1985	Johnson	546	269	09/30/1982
VB	A5	5,436,246	07/25/1995	Bernotàs et al.	514	255	09/15/1993
VB	A6	5,747,508	05/05/1998	Richter et al.	514	320	12/06/1996
VB	A7	5,858,995	01/12/1999	Kawai et al.	514	100	
VB	A8	6,302,837	10/16/1901	De Nanteuil et al.	574	337	10/13/2000

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION

		DOCUMENT NUMBER	PUBLIC-ATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUB CLASS	TRANS-LATION YES	TRANS-LATION NO
VB	B1	0 512 570	11.10.1995	EP				
VB	B2	0 982 300	01.03.2000	EP				
VB	B3	01/23380	05.04.2001	WO				
VB	B4	02/10156	07.02.2002	WO				
VB	B5	95/04052	09.02.1995	WO				
VB	B6	95/29907	09.11.1995	WO				
VB	B7	96/11192	18.04.1996	WO				
VB	B8	98/38188	03.09.1998	WO				
VB	B9	98/52946	26.11.1998	WO				
VB	B10	99/61435	02.12.1999	WO				

OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)

VB	C1	Descamps et al., "Benzofurans. XLII. Synthesis of 2-benzofurylmethylamines and amides of coumarilic acids," Chimica therapeutica 5(3):169-184 (1970)
VB	C2	JP 07173158 Abstracts

EXAMINER	V. Balasubramanian	DATE CONSIDERED	6/24/04

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

(Form PTO 1449)

DATE: April 14, 2004 SHEET _1_ of _3_

Form PTO - 1449 (Modified)

FORM PTO-1449 (Modified) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO.	SERIAL NO.
	6791US02	10/081,207
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	APPLICANT(S) Cowart, et al.	
(Use several sheets if necessary)	FILING DATE February 25, 2002	GROUP 1624
(37 CFR 1.98 (b))		

U.S.PATENT DOCUMENTS

EXAMINER INITIAL		PATENT NUMBER	ISSUE DATE	INVENTOR	CLASS	SUB CLASS	FILING DATE

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION

		DOCUMENT NUMBER	PUBLICATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUB CLASS	TRANS-LATION YES	NO

OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)

M	C1	Bjenning et al., "Peripherally Administered Ciproxifan Elevates Hypothalamic Histamine Levels And Potently Reduces Food Intake in the Sprague Dawley Rat," Histamine Research In The New Mellennium, Proceedings Of The International Sendai Histamine Symposium Held In Sendai, Japan, 22-25 November 2000, p. 449-450
M	C2	De Almeida et al., "Memory Facilitation by Histamine," Arch. Int. Pharmacodyn., 283:193-198 (1986).
M	C3	Delaunois et al., "Modulation Of Acetylcholine, Capsaicin and Substance P Effects by Histamine H_3 Receptors in Isolated Perfused Rabbit Lungs," European Journal Of Pharmacology, 277:243-250 (1995).
M	C4	Dimitriadou et al., "Functional Relationship Between Mast Cells and C-Sensitive Nerve Fibres Evidenced by Histamine H_3-Receptor Modulation in Rat Lung and Spleen," Clinical Science, 87:151-163 (1994).
M	C5	Duméry et al., "Development of Amygdaloid Cholinergic Mediation of Passive Avoidance Learning in the Rat," Exp. Brain. Res., 67:61-69 (1987).
M	C6	Ellingboe et al., "Antihyperglycemic Activity of Novel Naphthalenyl 3*H*-1,2,3,5-Oxathiadiazole 2-Oxides," J. Med. Chem. 36:2485-2493 (1993)
M	C7	Fitzsimons et al., "Histamine Receptors Signalling in Epidermal Tumor Cell Lines With H-*ras* Gene Alterations," Inflamm. Res., 47, Supplement 1, S50-S51 (1998).
M	C8	Haas et al., Subcortical Modulation of Synaptic Plasticity in the Hippocampus," Behavioural Brain Research, 66:41-44 (1995).
M	C9	Hatta et al., "Activation of Histamine H_3 Receptors Inhibits Carrier-Mediated Norepinephrine Release in a Human Model of Protracted Myocardial Ischemia[1,2]," The Journal Of Pharmacology And Experimental Therapeutics, 283(2):494-500 (1997).
M	C10	Imamura et al., "Activation Of Histamine H_3-Receptors Inhibits Carrier-Mediated Norepinephrine Release During Protracted Myocardial Ischemia," Circulation Research, 78(3):475-481 (1996).
M	C21	Imamura et al., "Histamine H_3-Receptor-Mediated Inhibition Of Calcitonin Gene-Related Peptide Release From Cardiac C Fibers," Circulation Research, 78(5):863-869 (1996).

	C14	Kamei et al., "Participation Of Histamine In The Step-Through Active Avoidance Response And Its Inhibition By H_1-Blockers," Japan J. Pharmacol., 57:473-482 (1991).
	C15	Leurs et al., "The Histamine H_3-Receptor: A Target For Developing New Drugs," Progress In Drug Research, 39:127-165 (1992).
	C16	Leurs et al., "The Medicinal Chemistry And Therapeutic Potentials Of Ligands Of The Histamine H_3 Receptor," Progress In Drug Research, 45:107-165 (1995).
	C17	Leurs et al., "Therapeutic Potential Of Histamine H_3 Receptor Agonists And Antagonists," Trends In Pharm. Sci, 19:177-183 (1998).
	C18	Levi et al., "Histamine H_3-Receptors: A New Frontier In Myocardial Ischemia," The Journal Of Pharmacology And Experimental Therapeutics, 292(3):825-830 (2000).
	C19	Lin et al., "Involvement Of Histaminergic Neurons In Arousal Mechanisms Demonstrated With H_3-Receptor Ligands In The Cat," Brain Research, 523:325-330 (1990).
	C20	Matsubara et al., "UK-14,304, R(-) α-Methyl-Histamine And SMS 201-995 Block Plasma Protein Leakage Within Dura Mater By Prejunctional Mechanisms," European Journal Of Pharmacology, 224:145-150 (1992).
	C21	Mazurkiewicz-Kwilecki et al., "Changes In The Regional Brain Histamine And Histidine Levels In Postmortem Brains Of Alzheimer Patients," Can. J. Physiol. Pharmacol, 67: 75-78 (1989).
	C22	McLeod et al., "Histamine H_3 Antagonists," Progress In Resp. Research 31:133-134 (2001)
	C23	Monti et al., "Effects Of Selective Activation Or Blockade Of The Histamine H_3 Receptor On Sleep And Wakefulness," European Journal Of Pharmacology, 205:283-287 (1991).
	C24	Monti et al., "Sleep And Waking During Acute Histamine H_3 Agonist BP2.94 Or H_3 Antagonist Carboperamide (MR 16155) Administration In Rats," Neuropsychopharmacology, 15(1):31-35 (1996).
	C25	Murakami et al., "AQ-0145, A Newly Developed Histamine H_3 Antagonist, Decreased Seizure Susceptibility Of Electrically Induced Convulsions In Mice," Meth. Find. Exp. Clin. Pharmacol. 17(C):70-73 (1995)
	C26	Onodera et al., "Neuropharmacology Of The Histaminergic Neuron System In The Brain And Its Relationship With Behavioral Disorders," Progress In Neurobiology, 42:685-702 (1994).
	C27	Panula et al., "Histamine Neurons in Human Hypothalamus: Anatomy in Normal and Alzheimer Diseased Brains," Neuroscience 44(2):465-481 (1991)
	C28	Panula et al., "Neuronal Histamine Deficit in Alzheimer's Disease," Neuroscience 82(4):993-997 (1998)
	C29	Perez-Garcia et al., "Effects Of Histamine H_3 Receptor Ligands In Experimental Models Of Anxiety And Depression," Psychopharmacology 142:215-220 (1999)
	C30	Phillips et al., "Recent Advances In Histamine H_3 Receptor Agents," Annual Reports In Medicinal Chemistry, 33:31-40 (1998).
	C31	Rouleau, "Bioavailability, Antinociceptive And Antiinflammatory Properties Of BP 2-94, A Histamine H_3 Receptor Agonist Prodrug," The Journal Of Pharmacology And Experimental Therapeutics, 281(3):1085-1094 (1997).
	C32	Sakai et al., "Effects Of Thioperamide, A Histamine H_3 Receptor Antagonist, On Locomotor Activity And Brain Histamine Content In Mast Cell-Deficient W/W^V Mice," Life Sciences, 48:2397-2404 (1991).
	C33	Schwartz et al., "Histaminergic Transmission in the Mammalian Brain," Physiological Reviews 71(1):1-51 (1991)
	C34	Schwartz et al., "Histamine," Psychopharmacology: The Fourth Generation Of Progress, 397-405 (1995).
	C35	Shaywitz et al., "Dopaminergic But Not Noradrenergic Mediation Of Hyperactivity And Performance Deficits In The Developing Rat Pup," Psychopharmacology, 82:73-77 (1984).
	C36	Szelag, "Role Of Histamine H_3-Receptors In The Proliferation Of Neoplastic Cells In Vitro," Med. Sci. Monit., 4(5):747-755 (1998).
	C37	Tedford et al., "Cognition And Locomotor Activity In The Developing Rat: Comparisons Of Histamine H_3 Receptor Antagonists And ADHD Therapeutics," Society For Neuroscience Abstr., 22:22 (1996).
	C38	Tedford et al., "Pharmacological Characterization Of GT-2016, A Non-Thiourea-Containing Histamine H_3 Receptor Antagonist: *In Vitro* And *In Vivo* Studies," The Journal Of Pharmacology And Experimental Therapeutics, 275(2):598-604 (1995).
	C39	Wada et al., "Is The Histaminergic Neuron System A Regulatory Center For Whole-Brain Activity?, "Trends In Neurosciences, 14(9):415-418 (1991).

	C40	Yates et al., "Effects Of A Novel Histamine H_3 Receptor Antagonist, GT-2394, On Food Intake And Weight Gain In Sprague-Dawley Rats," Abstracts, Society For Neuroscience, 102.10:219 (November 2000)
	C41	Yokoyama et al., "Effect Of Thioperamide, A Histamine H_3 Receptor Antagonist, On Electrically Induced Convulsions In Mice," Journal Of Pharmacology, 234:129-133 (1993).
	C42	Yokoyama et al., "Histamine And Seizures Implications For The Treatment Of Epilepsy," CNS Drugs, 5(5):321-330 (1996).

EXAMINER V. Balasubramaniam | DATE CONSIDERED 6/24/04

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

(Form PTO 1449)